Business News / Markets

InVivo Therapeutics Shares Skyrocket 75% on Neuro-Spinal Scaffold Results

InVivo Therapeutics (NVIV) surged to their highest level in nearly two months after the company presented data from the INSPIRE study of its neuro-spinal scaffold indicating 44% of the patients enrolled in the study reached its primary endpoint.

The results were presented at the 2018 American Association of Neurological Surgeons Annual Scientific Meeting

This was the first presentation at a medical meeting of the complete six-month data from the INSPIRE study.

InVivo has officially closed the INSPIRE study and has received supplemental investigational device exemption approval from the U.S. Food and Drug Administration for a second pivotal clinical study of the company’s neuro-spinal scaffold in patients with acute spinal cord injury.